The clinical efficacy of combination therapy with amikacin, imipenem/cilastatin sodium and granulocyte colony-stimulating factor on infection in neutropenic patients with hematologic diseases

K. Toyama, M. Yaguchi, Shinichiro Okamoto, Y. Masuda, I. Aoki, M. Kitahara, Y. Takahashi, M. Kawato, T. Boku, K. Izawa, Y. Uchida, K. Wakasugi, M. Kikuchi, N. Tsuruoka, M. Koike, T. Ohshima, M. Kawamura

Research output: Contribution to journalArticle

Abstract

The clinical efficacy of combination therapy with amikacin (AMK), imipenem/cilastatin sodium (IPM/CS) and recombinant human granulocyte colony- stimulating factor (G-CSF) was evaluated in 32 neutropenic patients with hematological diseases. Clinical effectiveness was observed in 24 cases (including 3 cases of sepsis), an efficacy rate of 75.0%. The efficacy rate was 90% in the l0 patients with neutrophil counts less than 100/μl at the time of therapeutic evaluation. It was 81.1% (9/11) in patients whose neutrophil counts increased 20% or more during treatment and 66.7% (8/12) in patients whose neutrophil counts increased less than 20%; the difference in efficacy rates was not statistically significant. A clinical efficacy rate of 75.9% was observed in 29 neutropenic patients chosen according to the same criteria as those of the present study from among patients who were treated with AMK plus IPM/CS in a previous study (the historical controls . When the results in the historical control group were compared with those in the (G- CSF group, there was no significant difference in efficacy rate, profile of body temperature or duration of fever. The results suggest that combination therapy with AMK and IPM/CS is very effective in treating infections in neutropenic patients, with or without G-CSF.

Original languageEnglish
Pages (from-to)753-760
Number of pages8
JournalJapanese Journal of Chemotherapy
Volume44
Issue number9
Publication statusPublished - 1996 Sep
Externally publishedYes

Fingerprint

Cilastatin
Amikacin
Hematologic Diseases
Granulocyte Colony-Stimulating Factor
Infection
Neutrophils
Therapeutics
imipenem drug combination cilastatin
Body Temperature
Sepsis
Fever
Control Groups

Keywords

  • amikacin
  • imipenem/cilastatin sodium
  • rhG-CSF

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

The clinical efficacy of combination therapy with amikacin, imipenem/cilastatin sodium and granulocyte colony-stimulating factor on infection in neutropenic patients with hematologic diseases. / Toyama, K.; Yaguchi, M.; Okamoto, Shinichiro; Masuda, Y.; Aoki, I.; Kitahara, M.; Takahashi, Y.; Kawato, M.; Boku, T.; Izawa, K.; Uchida, Y.; Wakasugi, K.; Kikuchi, M.; Tsuruoka, N.; Koike, M.; Ohshima, T.; Kawamura, M.

In: Japanese Journal of Chemotherapy, Vol. 44, No. 9, 09.1996, p. 753-760.

Research output: Contribution to journalArticle

Toyama, K, Yaguchi, M, Okamoto, S, Masuda, Y, Aoki, I, Kitahara, M, Takahashi, Y, Kawato, M, Boku, T, Izawa, K, Uchida, Y, Wakasugi, K, Kikuchi, M, Tsuruoka, N, Koike, M, Ohshima, T & Kawamura, M 1996, 'The clinical efficacy of combination therapy with amikacin, imipenem/cilastatin sodium and granulocyte colony-stimulating factor on infection in neutropenic patients with hematologic diseases', Japanese Journal of Chemotherapy, vol. 44, no. 9, pp. 753-760.
Toyama, K. ; Yaguchi, M. ; Okamoto, Shinichiro ; Masuda, Y. ; Aoki, I. ; Kitahara, M. ; Takahashi, Y. ; Kawato, M. ; Boku, T. ; Izawa, K. ; Uchida, Y. ; Wakasugi, K. ; Kikuchi, M. ; Tsuruoka, N. ; Koike, M. ; Ohshima, T. ; Kawamura, M. / The clinical efficacy of combination therapy with amikacin, imipenem/cilastatin sodium and granulocyte colony-stimulating factor on infection in neutropenic patients with hematologic diseases. In: Japanese Journal of Chemotherapy. 1996 ; Vol. 44, No. 9. pp. 753-760.
@article{743ae8621e104a43926e0b21fa418ec0,
title = "The clinical efficacy of combination therapy with amikacin, imipenem/cilastatin sodium and granulocyte colony-stimulating factor on infection in neutropenic patients with hematologic diseases",
abstract = "The clinical efficacy of combination therapy with amikacin (AMK), imipenem/cilastatin sodium (IPM/CS) and recombinant human granulocyte colony- stimulating factor (G-CSF) was evaluated in 32 neutropenic patients with hematological diseases. Clinical effectiveness was observed in 24 cases (including 3 cases of sepsis), an efficacy rate of 75.0{\%}. The efficacy rate was 90{\%} in the l0 patients with neutrophil counts less than 100/μl at the time of therapeutic evaluation. It was 81.1{\%} (9/11) in patients whose neutrophil counts increased 20{\%} or more during treatment and 66.7{\%} (8/12) in patients whose neutrophil counts increased less than 20{\%}; the difference in efficacy rates was not statistically significant. A clinical efficacy rate of 75.9{\%} was observed in 29 neutropenic patients chosen according to the same criteria as those of the present study from among patients who were treated with AMK plus IPM/CS in a previous study (the historical controls . When the results in the historical control group were compared with those in the (G- CSF group, there was no significant difference in efficacy rate, profile of body temperature or duration of fever. The results suggest that combination therapy with AMK and IPM/CS is very effective in treating infections in neutropenic patients, with or without G-CSF.",
keywords = "amikacin, imipenem/cilastatin sodium, rhG-CSF",
author = "K. Toyama and M. Yaguchi and Shinichiro Okamoto and Y. Masuda and I. Aoki and M. Kitahara and Y. Takahashi and M. Kawato and T. Boku and K. Izawa and Y. Uchida and K. Wakasugi and M. Kikuchi and N. Tsuruoka and M. Koike and T. Ohshima and M. Kawamura",
year = "1996",
month = "9",
language = "English",
volume = "44",
pages = "753--760",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "9",

}

TY - JOUR

T1 - The clinical efficacy of combination therapy with amikacin, imipenem/cilastatin sodium and granulocyte colony-stimulating factor on infection in neutropenic patients with hematologic diseases

AU - Toyama, K.

AU - Yaguchi, M.

AU - Okamoto, Shinichiro

AU - Masuda, Y.

AU - Aoki, I.

AU - Kitahara, M.

AU - Takahashi, Y.

AU - Kawato, M.

AU - Boku, T.

AU - Izawa, K.

AU - Uchida, Y.

AU - Wakasugi, K.

AU - Kikuchi, M.

AU - Tsuruoka, N.

AU - Koike, M.

AU - Ohshima, T.

AU - Kawamura, M.

PY - 1996/9

Y1 - 1996/9

N2 - The clinical efficacy of combination therapy with amikacin (AMK), imipenem/cilastatin sodium (IPM/CS) and recombinant human granulocyte colony- stimulating factor (G-CSF) was evaluated in 32 neutropenic patients with hematological diseases. Clinical effectiveness was observed in 24 cases (including 3 cases of sepsis), an efficacy rate of 75.0%. The efficacy rate was 90% in the l0 patients with neutrophil counts less than 100/μl at the time of therapeutic evaluation. It was 81.1% (9/11) in patients whose neutrophil counts increased 20% or more during treatment and 66.7% (8/12) in patients whose neutrophil counts increased less than 20%; the difference in efficacy rates was not statistically significant. A clinical efficacy rate of 75.9% was observed in 29 neutropenic patients chosen according to the same criteria as those of the present study from among patients who were treated with AMK plus IPM/CS in a previous study (the historical controls . When the results in the historical control group were compared with those in the (G- CSF group, there was no significant difference in efficacy rate, profile of body temperature or duration of fever. The results suggest that combination therapy with AMK and IPM/CS is very effective in treating infections in neutropenic patients, with or without G-CSF.

AB - The clinical efficacy of combination therapy with amikacin (AMK), imipenem/cilastatin sodium (IPM/CS) and recombinant human granulocyte colony- stimulating factor (G-CSF) was evaluated in 32 neutropenic patients with hematological diseases. Clinical effectiveness was observed in 24 cases (including 3 cases of sepsis), an efficacy rate of 75.0%. The efficacy rate was 90% in the l0 patients with neutrophil counts less than 100/μl at the time of therapeutic evaluation. It was 81.1% (9/11) in patients whose neutrophil counts increased 20% or more during treatment and 66.7% (8/12) in patients whose neutrophil counts increased less than 20%; the difference in efficacy rates was not statistically significant. A clinical efficacy rate of 75.9% was observed in 29 neutropenic patients chosen according to the same criteria as those of the present study from among patients who were treated with AMK plus IPM/CS in a previous study (the historical controls . When the results in the historical control group were compared with those in the (G- CSF group, there was no significant difference in efficacy rate, profile of body temperature or duration of fever. The results suggest that combination therapy with AMK and IPM/CS is very effective in treating infections in neutropenic patients, with or without G-CSF.

KW - amikacin

KW - imipenem/cilastatin sodium

KW - rhG-CSF

UR - http://www.scopus.com/inward/record.url?scp=10244257586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10244257586&partnerID=8YFLogxK

M3 - Article

VL - 44

SP - 753

EP - 760

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - 9

ER -